Pregnancy Outcome Prediction Study University Department of Obstetrics and Gynaecology; PI – Professor Gordon CS Smith BACKGROUND The current pattern of provision of antenatal care for low risk women in the UK was established in The primary purpose of ante-natal care is to monitor fetal wellbeing and to screen for maternal complications of pregnancy. The approach to screening for complications of pregnancy such as intra-uterine growth restriction, pre-eclampsia and stillbirth has remained largely unchanged for many years and includes measurement of blood pressure and symphysis fundal height, plus urinalysis. Randomised controlled trials of more high tech screening methods, such as utero-placental Doppler flow velocimetry and ultrasonic fetal biometry in the general population have generally failed to show improvements in outcome. A range of ultrasonic and biochemical markers of abnormal placentation have been described, but their utility in planning clinical care remains uncertain. In a previous review of literature on stillbirth we concluded that “future work on population- based screening for stillbirth should be preceded by high-quality, non- interventional prospective cohort studies, characterising the screening properties of new methods of risk assessment in an unselected population” (Smith & Fretts, Lancet 2007;370: ). AIMS 1.To identify novel genetic and molecular markers for adverse perinatal outcome 2.To develop an integrated method of screening pregnant women to determine their risk of adverse perinatal outcomes. STUDY DESIGN This is a 5-year prospective cohort study of women attending for antenatal care at the Rosie Hospital. The study aims to recruit approximately 4,000 women in their first pregnancy. Participation will involve (1) obtaining clinical and socio-demographic information, (2) additional ultrasound scans and (3) collection of biological samples from participant, partner and placenta. PROGRESS Recruitment commenced on 14 th January In the first 18 months of the study a total of 2096 eligible women were approached and 1211 (57.8%) agreed to participate in the study. In this period, a total of 2520 research scans have been performed in Addenbrooke’s Clinical Investigation Ward. 692 women have completed the ante-natal component of the study. Only 3.3% (n=40) have not completed the study. Most of these women have transferred their care to another hospital. Serum and plasma samples are collected at the 12,20,28 and 36-week visits. A total of 3668 serum and plasma samples have been collected. Maternal and paternal DNA samples are collected at the 20-week visit and a total of 972 samples have been collected. The projected collection in the bio-bank are on Figure 1. The Study Pathway Booking visit (~12 weeks) Medical and socio- demographic factors Ultrasonic measurements Maternal serum and plasma samples Scans at 20, 28 & 36 weeks Ultrasonic measurements for fetal growth and placental function Maternal serum and plasma samples Maternal & paternal samples for DNA At delivery Pregnancy and labour outcome Fetal cord blood Placental samples for RNA, DNA, gene expression and histology The POPS Biobank PATIENT ANTENA TAL Plasma & serum samples at 12, 20, 28 & 36 weeks Maternal whole blood for DNA at 20 weeks Paternal saliva for DNA BIRTH UMBILIC AL CORD For fetal DNA Cord blood plasma and serum Fixed in Formalin PLACEN TA For RNA For DNA/Prot ein Fixed in Formalin MEMBR ANE Fixed in Formalin Samples collected & projected size of biobank